1,2,3-Tri-O-benzoyl-4,6-O-benzylidene-b-D-glucopyranose - CAS 113544-56-2
Category:
Carbohydrates
Product Name:
1,2,3-Tri-O-benzoyl-4,6-O-benzylidene-b-D-glucopyranose
CAS Number:
113544-56-2
Molecular Weight:
580.58
Molecular Formula:
C34H28O9
COA:
Inquire
MSDS:
Inquire
Structure:
Monosaccharides
Chemical Structure
CAS 113544-56-2 1,2,3-Tri-O-benzoyl-4,6-O-benzylidene-b-D-glucopyranose

Related Monosaccharides Products


Reference Reading


1.Follow-up of Women With Negative Pap Test Results and Abnormal Clinical Signs or Symptoms.
Ocque R1, Austin RM1. Am J Clin Pathol. 2016 Apr 22. pii: aqw040. [Epub ahead of print]
OBJECTIVES: Abnormal signs or symptoms recorded on Papanicolaou (Pap) test requisitions may reflect disease not detected with Pap testing. Since 2009, these cases have been reviewed in our laboratory by a second cytotechnologist and a cytopathologist. The objective of this study was to document follow-up findings on these patients.
2.Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Loghavi S1, Bueso-Ramos CE1, Kanagal-Shamanna R1, Young Ok C1, Salim AA1, Routbort MJ1, Mehrotra M1, Verstovsek S2, Medeiros LJ1, Luthra R1, Patel KP3. Am J Clin Pathol. 2016 Mar;145(3):418-427.
OBJECTIVES: Calreticulin (CALR) mutations are present in 50% to 85% of JAK2/MPL wild-type (wt) myeloproliferative neoplasms (MPNs). The histopathologic features of CALR-mutated MPNs are unknown.
3.IFITM1 Is Superior to CD10 as a Marker of Endometrial Stroma in the Evaluation of Myometrial Invasion by Endometrioid Adenocarcinoma.
Busca A1, Djordjevic B1, Giassi A1, Parra-Herran C2. Am J Clin Pathol. 2016 Mar 21. pii: aqw021. [Epub ahead of print]
BACKGROUND: Distinguishing myometrial invasion from adenomyosis involvement is important for staging of endometrial endometrioid adenocarcinoma. We aimed to compare CD10, which has limited value in this scenario, with interferon-induced transmembrane protein 1 (IFITM1), a recently described sensitive and specific marker of endometrial stroma.
4.Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?
Prendeville S1, Corrigan MA2, Livingstone V2, Feeley L1, Bennett MW1, Browne TJ1, O'Connell F3. Am J Clin Pathol. 2016 Mar;145(3):316-322.
OBJECTIVES: The purpose of this study was to determine the optimum number of cells that should be counted when scoring human epidermal growth factor receptor 2 (HER2) brightfield dual-color in situ hybridization (BDISH), including cases with HER2/chromosome 17 (Chr17) ratios in the 1.80 to 2.20 range.